Experienced in Contact Dermatitis

Dr. Craig Leonardi

Dermatology
Central Dermatology P.C.
1034 S Brentwood Blvd Ste 600, 
Saint Louis, MO 
Experienced in Contact Dermatitis
Central Dermatology P.C.
1034 S Brentwood Blvd Ste 600, 
Saint Louis, MO 

Overview

Craig Leonardi is a Dermatologist in Saint Louis, Missouri. Dr. Leonardi is rated as an Experienced provider by MediFind in the treatment of Contact Dermatitis. His top areas of expertise are Psoriasis, Plaque Psoriasis, Atopic Dermatitis, and Contact Dermatitis.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Contact Dermatitis.

Specialties

Dermatology

Licenses

Dermatology in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Central Dermatology P.C.
1034 S Brentwood Blvd Ste 600, Saint Louis, MO 63117

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
Enrollment Status: Terminated
Publish Date: March 15, 2022
Intervention Type: Drug
Study Drugs: LY3462817-IV, LY3462817-SV
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: June 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

112 Total Publications

Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.
Journal: Dermatology and therapy
Published: May 31, 2024
Similar Doctors
Distinguished in Contact Dermatitis
Dr. Connie Gibstine
Dermatology
Distinguished in Contact Dermatitis
Dr. Connie Gibstine
Dermatology

St Louis Medical Clinic PC

3009 N Ballas Rd Ste 100B, 
Saint Louis, MO 
 (5.5 miles away)
314-994-0200
Languages Spoken:
English
See accepted insurances

Connie Gibstine is a Dermatologist in Saint Louis, Missouri. Dr. Gibstine is rated as a Distinguished provider by MediFind in the treatment of Contact Dermatitis. Her top areas of expertise are Contact Dermatitis, Universal Acquired Melanosis, Liver Spots, and Actinic Keratosis.

Distinguished in Contact Dermatitis
Dr. Susan Journagan
Dermatology
Distinguished in Contact Dermatitis
Dr. Susan Journagan
Dermatology

Office

390 Office Ct, 
Fairview Heights, IL 
 (19.9 miles away)
618-233-7666
Languages Spoken:
English
See accepted insurances

Susan Journagan is a Dermatologist in Fairview Heights, Illinois. Dr. Journagan is rated as a Distinguished provider by MediFind in the treatment of Contact Dermatitis. Her top areas of expertise are Actinic Keratosis, Rosacea, Comedones, and Seborrheic Keratosis.

Distinguished in Contact Dermatitis
Dr. Courtney Tobin
Dermatology
Distinguished in Contact Dermatitis
Dr. Courtney Tobin
Dermatology

Office

390 Office Ct, 
Fairview Heights, IL 
 (19.9 miles away)
618-233-7666
Languages Spoken:
English
See accepted insurances

Courtney Tobin is a Dermatologist in Fairview Heights, Illinois. Dr. Tobin is rated as a Distinguished provider by MediFind in the treatment of Contact Dermatitis. Her top areas of expertise are Actinic Keratosis, Comedones, Griscelli Syndrome, and Dyschromatosis Universalis Hereditaria.

Frequently Asked Questions about Dr. Craig Leonardi

How do I make an appointment with Dr. Craig Leonardi?

You can book an appointment with Dr. Craig Leonardi by calling their office at 314-721-5565. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig Leonardi a top-rated expert for Psoriasis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig Leonardi is classified as an Elite expert for Psoriasis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig Leonardi specialize in?

While Dr. Craig Leonardi is a Dermatology, they have specific expertise in Psoriasis, Plaque Psoriasis, and Atopic Dermatitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Craig Leonardi participate in research or clinical trials?

Yes. Dr. Craig Leonardi has published 112 articles and abstracts on conditions like Psoriasis. You can view a list of Dr. Craig Leonardi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig Leonardi accept my insurance?

Dr. Craig Leonardi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-721-5565 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Leonardi's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile